Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulopenem
- Development stage
- Phase 3
- Lead developer
- Iterum Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sulopenem is a broad-spectrum thiopenem β-lactam antibiotic developed for the treatment of infections caused by multidrug-resistant bacteria. It is active against both Gram-negative and Gram-positive organisms, including fluoroquinolone-resistant and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. Sulopenem exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), with the highest affinity for PBP2. The drug is available in both intravenous form and as an oral prodrug (sulopenem etzadroxil), which is hydrolyzed in the body to release active sulopenem. When administered orally, it is co-formulated with probenecid to inhibit renal clearance and increase systemic exposure. Sulopenem has been approved for use in combination with probenecid under the brand name Orlynvah for treating uncomplicated urinary tract infections (uUTI) in adult women who have limited or no alternative oral antibacterial options[3][4][5][6][7].
- Brand names
- Orlynvah
- Other names
- sulopenem etzadroxil
02
Targets
PBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)PBP2 (Penicillin-binding protein 2)PBP4 (Penicillin-binding protein 4)PBP5 (D-alanyl-D-alanine carboxypeptidase DacA)
Beyond the preview
Go deeper on sulopenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulopenem.